ABSTRACT
Background Circulating tumor cells (CTCs) have a strong potential as a quasi-non-invasive tool to set up precision medicine strategy for cancer patients. Tremendous efforts have been made to develop the second-generation of “filtration-based” technologies to detect CTCs, revealing a surprising heterogeneity among those cells. Here, we performed the largest and simultaneous analysis of all atypical circulating tumor cells (aCTCs) detected with a filtration-based technology, in a cohort of metastatic breast cancer (mBC) patients, and correlated their presence with clinicopathological and survival data.
Methods The PERMED-01 study enrolled patients with mBC refractory to systemic therapy. We prospectively analyzed aCTCs present at the time of inclusion in the study, using the Screencell®Cyto device (n=91). Subsets cut-offs were established and evaluated for correlation with clinicopathological data, including progression-free survival (PFS) and overall survival (OS).
Results The median number of aCTCs found in mBC was 8.3 per mL of blood. Three subsets of aCTCs, absent from controls, were observed in mBC patients: single (s-aCTCs), circulating tumor micro-emboli (CTM), and giant-aCTCs (g-aCTCs). The presence of g-aCTCs was associated with shorter PFS and OS in multivariate analyses. For 23 cases, the analysis was completed with advanced immunofluorescence staining and showed that CTM and g-aCTCs displayed a hybrid phenotype for epithelial and mesenchymal markers.
Conclusions This study highlights the heterogeneity of aCTCs in mBC patients both at the cytomorphological and molecular levels when using a Screencell®Cyto device. It reveals the g-aCTC subset as a prognostic factor and a potential stratification tool that might help to orientate late-stage mBC patients’ therapeutic care.
Competing Interest Statement
AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.
Clinical Trial
NCT02342158
Funding Statement
This work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (PDF20180507565) and the Fondation de France (00107936). Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National ethics committee (CPP Sud-Mediterranee) registered as identifier NCT02342158 at the ClinicalTrials.gov platform
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available on request
Abbreviations
- aCTCs
- atypical Circulating Tumor Cells
- CAMLs
- Cancer-Associated Macrophage-Like cells
- CTCs
- Circulating Tumor Cells
- CTM
- Circulating tumor micro-emboli
- E/M status
- Epithelial to Mesenchymal status
- EMT
- Epithelial to Mesenchymal Transition
- g-aCTC
- giant-atypical Circulating Tumor Cells
- GMM
- Gaussian finite Mixture Model
- LR
- Likelihood Ratio
- mBC
- metastatic breast cancer
- MGG
- May Grünwald Giemsa
- N/C
- nucleocytoplasmic
- OS
- Overall survival
- PBS
- Phosphate Buffered Saline
- PFS
- Progression free survival
- RT
- room temperature
- s-aCTC
- single-atypical Circulating Tumor Cells
- TAM
- Tumor Associated Macrophage
- TN
- Triple Negative
